PureTech Health plc (PTCHF)
OTCMKTS
· Delayed Price · Currency is USD
1.740
+0.040 (2.35%)
Feb 20, 2025, 3:00 PM EST
PureTech Health Revenue
PureTech Health had revenue of $288.00K in the half year ending June 30, 2024, a decrease of -95.90%. This brings the company's revenue in the last twelve months to $468.00K, down -96.01% year-over-year. In the year 2023, PureTech Health had annual revenue of $3.33M, down -78.68%.
Revenue (ttm)
468.00K
Revenue Growth
-96.01%
P/S Ratio
n/a
Revenue / Employee
5.20K
Employees
90
Market Cap
429.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
| Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
| Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
| Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
| Dec 31, 2019 | 9.81M | -10.94M | -52.73% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 21.77M |
| BioStem Technologies | 210.49M |
PureTech Health News
- 10 days ago - CITIGROUP INC Acquires 10,703,044 Shares in PureTech Health PLC - GuruFocus
- 10 days ago - PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform - Business Wire
- 26 days ago - PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine - Business Wire
- 6 weeks ago - Zentalis Pharmaceuticals and PureTech Health get Fast Track Designation from FDA for their cancer treatments - Seeking Alpha
- 6 weeks ago - PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML) - Business Wire
- 6 weeks ago - PureTech Appoints UBS as UK Corporate Broker - Business Wire
- 2 months ago - Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Benzinga
- 2 months ago - PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial - Business Wire